Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

Share Price is delayed by 15 minutes
Get Live Data
5,975.00    -40.00 (-0.67%)
Bid:
5,990.00
Ask:
5,995.00
Spread: 5.00 (0.083%)
Market Cap: £5.10b
DCC Live PriceLast checked at - London Stock Exchange

Intraday DCC Share Chart

Man Group PLC : Form 8.3 - DCC Plc

8 Jun 2026 11:33

Man Group PLC : Form 8.3 - DCC Plc

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVERRULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

(a) Full name of discloserMan Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offereeDCC plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) 
(e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure05/06/2026
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”No

2. INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)(Note 2)

Class of relevant security (Note 3)€0.25 Ordinary Shares
 InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled2,210,1022.59  
(2) Cash-settled derivatives414,730.000.4913,992.000.02
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell    
Total2,624,8323.0713,992.000.02

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevantsecurityPurchase/saleNumber ofsecuritiesPrice per unit(Note 5)

Ap29

(b) Cash-settled derivative transactions

Class ofrelevantsecurityProduct description e.g. CFDNature of dealinge.g. opening/ closing a long/ short position, increasing/ reducing a long/ short positionNumber ofreference securities (Note 6)Price per unit (Note 5)
€0.25 OrdinaryEquity SwapIncreasing a long position17160.2668 EUR

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relates (Note 6)Exerciseprice per unitType e.g. American, Europeanetc.Expiry dateOption moneypaid/ received per unit

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 3)

Class of relevant securityNature of dealing e.g. subscription, conversion, exerciseDetailsPrice per unit (if applicable) (Note 5)

Ap30

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
 None

(b) Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 None

(c) Attachments

Is a Supplemental Form 8 attached?NO

Date of disclosure08/06/2026
Contact nameMolly Childs
Telephone number+442071443714

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

Ap31

NOTES ON FORM 8.3

1. See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.

2. See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.

3. See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.

4. See the definition of “dealing” in Rule 2.1 of Part A of the Rules.

5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

6. See Rule 2.5(d) of Part A of the Rules.

7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Date   Source Headline
17th Nov 202010:16 amRNSDirector/PDMR Shareholding
13th Nov 20203:40 pmRNSDirector/PDMR Shareholding
10th Nov 20207:00 amRNSResults for the six months ended 30 September 2020
4th Nov 20204:35 pmRNSHolding in Company TR-1
29th Oct 20207:15 amRNSDirector Declaration
23rd Oct 20204:30 pmRNSHolding in Company TR-1
23rd Oct 20209:38 amRNSUpcoming Events
19th Oct 20203:51 pmRNSHolding in Company TR-1
14th Oct 20204:16 pmRNSHolding in Company TR-1
6th Oct 20203:40 pmRNSHolding in Company TR-1
5th Oct 202012:29 pmRNSHolding in Company TR-1
5th Oct 20209:30 amRNSHolding in Company TR-1
1st Oct 20205:07 pmRNSHolding in Company TR-1
22nd Sep 20204:29 pmRNSHolding in Company TR-1
21st Sep 20207:00 amRNSDCC expands LPG business in the US and Netherlands
9th Sep 20203:18 pmRNSAppointment of General Counsel & Company Secretary
4th Sep 20204:10 pmRNSUpdate on LTIP Performance Condition Ranges
31st Jul 202012:52 pmRNSTotal Voting Rights
23rd Jul 20204:14 pmRNSHolding in Company TR-1
21st Jul 202011:42 amRNSDirector/PDMR Shareholding
20th Jul 20204:00 pmRNSHolding in Company TR-1
17th Jul 20201:59 pmRNSResult of AGM
17th Jul 20207:00 amRNSInterim Management Statement
14th Jul 20202:28 pmRNSHolding in Company TR-1
8th Jul 202011:38 amRNSHolding in Company TR-1
24th Jun 20209:39 amRNSHolding in Company TR-1
18th Jun 202012:25 pmRNS2020 Annual Report, Notice of AGM and Proxy Form
3rd Jun 202010:10 amRNSHolding in Company TR-1
29th May 202011:27 amRNSTotal Voting Rights
28th May 20206:21 pmRNSDirector/PDMR Shareholding
28th May 20201:02 pmRNSHolding in Company TR-1
19th May 20205:04 pmRNSBoard Changes
19th May 20207:00 amRNSResults for the year ended 31 March 2020
14th May 20203:30 pmRNSHolding in Company TR-1
27th Apr 20206:02 pmRNSDisclosure of Rights Attached to Equity Shares
16th Apr 20204:24 pmRNSDirector Declaration
9th Apr 20204:21 pmRNSHolding in Company TR-1
3rd Apr 20204:01 pmRNSHolding in Company TR-1
25th Mar 20203:22 pmRNSHolding in Company TR-1
25th Mar 20207:00 amRNSDCC Healthcare announces acquisition of Amerilab
19th Mar 20204:10 pmRNSHolding in Company TR-1
19th Mar 20209:46 amRNSHolding in Company TR-1
18th Mar 202012:14 pmRNSHolding in Company TR-1
6th Mar 20204:08 pmRNSHolding in Company TR-1
28th Feb 202010:54 amRNSTotal Voting Rights
24th Feb 20208:38 amRNSBoard Change
24th Feb 20208:34 amRNSChief Financial Officer Succession
12th Feb 20209:10 amRNSHolding in Company TR-1
4th Feb 20207:00 amRNSInterim Management Statement
17th Jan 20209:23 amRNSHolding in Company TR-1

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.